CAJ | 학술논문

目的：探讨不同BM I的T2DM患者血清β‐抑制蛋白2水平变化及与代谢指标的相关性。方法170例T2DM患者分为体重正常（Con）组55例、超重（Ow）组57例及肥胖（Ob）组58例，测定各组相关指标并行统计学分析。结果血清β‐抑制蛋白2水平在Con、Ow 及 Ob组分别为（331.31±11.59） vs （321.18±17.47） vs （303.95±13.63） ng／L ，组间两两比较，差异有统计学意义（ P＜0.05）。相关分析结果显示，β‐抑制蛋白2水平与BMI、TG、FIns、胰岛素抵抗指数（HOMA‐IR）、胰岛β细胞功能指数（HOMA‐β）呈负相关（r分别为－0.404、－0.328、－0.353、－0.308、－0.260，P＜0.01）；多元逐步回归分析显示，BMI与β‐抑制蛋白2水平独立相关，但未发现β‐抑制蛋白2与TG、FIns、HOMA‐IR及 HO‐MA‐β的相关性。结论 T2DM患者中，BMI是影响血清β‐抑制蛋白2水平降低的独立危险因素。
목적：탐토불동BM I적T2DM환자혈청β‐억제단백2수평변화급여대사지표적상관성。방법170례T2DM환자분위체중정상（Con）조55례、초중（Ow）조57례급비반（Ob）조58례，측정각조상관지표병행통계학분석。결과혈청β‐억제단백2수평재Con、Ow 급 Ob조분별위（331.31±11.59） vs （321.18±17.47） vs （303.95±13.63） ng／L ，조간량량비교，차이유통계학의의（ P＜0.05）。상관분석결과현시，β‐억제단백2수평여BMI、TG、FIns、이도소저항지수（HOMA‐IR）、이도β세포공능지수（HOMA‐β）정부상관（r분별위－0.404、－0.328、－0.353、－0.308、－0.260，P＜0.01）；다원축보회귀분석현시，BMI여β‐억제단백2수평독립상관，단미발현β‐억제단백2여TG、FIns、HOMA‐IR급 HO‐MA‐β적상관성。결론 T2DM환자중，BMI시영향혈청β‐억제단백2수평강저적독립위험인소。
Objective To investigate the levels of serum β‐arrestin 2 in type 2 diabetic (T2DM ) patients with different body mass index (BMI) and to analyze the association of serum β‐arrestin 2 with metabolic indices. Methods A total of 170 T2DM patients were enrolled and divided into three groups according to BMI as normal weight group (Con ,n=55) ,over‐weight group (Ow ,n=57) and obese group (Ob ,n= 58 ). Several related indices including blood chemistry values were determined and analyzed statistically. Results (1) Serum β‐arrestin 2 levels in Con group ,Ow group and Ob group were (331.31 ± 11.59 ) ,(321.18 ± 17.47 ) and (303.95 ± 13.63 ) ng/L respectively and the differences of pairwise comparison among three groups were statistically significant (P< 0.05). (2) Serum β‐arrestin 2 levels were negatively correlated with BMI ,TG ,FIns ,HOMA‐IR and HOMA‐β(r= -0.404 ,-0.328 ,-0.353 ,-0.308 ,-0.260 ,P<0.01). Multiple stepwise regression analysis showed that BMI was independently associated with serum β‐arrestin 2. TG ,FIns ,HOMA‐IR and HOMA‐βhad no association with the levels of serum β‐arrestin 2. Conclusion BMI is an independent risk factor for decreased levels of serum β‐arrestin 2 in T2DM patients.